Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of aprocitentan in resistant hypertension
2017-004393-33Phase 3Completed
- Sponsor
- Idorsia
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in resistant hypertension (RH) comparing Aprocitentan + standard of care with Standard of care (control) (2 arms). Primary endpoint: Primary endpoint: change in systolic blood pressure at Week 4. Started Apr 2018; status: completed.
02
Drugs
aprocitentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on 2017-004393-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004393-33.